-
1
-
-
84868207481
-
Ulcerative colitis
-
Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
-
(2012)
Lancet
, vol.380
, pp. 1606-1619
-
-
Ordas, I.1
Eckmann, L.2
Talamini, M.3
Baumgart, D.C.4
Sandborn, W.J.5
-
3
-
-
84991271465
-
Methotrexate for maintenance of remission in ulcerative colitis
-
Wang Y, MacDonald JK, Vandermeer B, Griffiths AM, El-Matary W. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;8:CD007560.
-
(2015)
Cochrane Database Syst Rev
, vol.8
-
-
Wang, Y.1
MacDonald, J.K.2
Vandermeer, B.3
Griffiths, A.M.4
El-Matary, W.5
-
4
-
-
84867359637
-
Vedolizumab for the treatment of ulcerative colitis and Crohn's disease
-
McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4:883-98.
-
(2012)
Immunotherapy
, vol.4
, pp. 883-898
-
-
McLean, L.P.1
Shea-Donohue, T.2
Cross, R.K.3
-
5
-
-
4344602852
-
Guidelines for the management of inflammatory bowel disease in adults
-
Carter MJ, Lobo AJ, Travis SP, IBD Section Bristish Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:v1-v16.
-
(2004)
Gut
, vol.53
, pp. V1-V16
-
-
Carter, M.J.1
Lobo, A.J.2
Travis, S.P.3
-
6
-
-
84925664186
-
Tumor necrosis factoralpha antagonists twenty years later: What do Cochrane reviews tell us?
-
Akobeng AA, Sandborn WJ, Bickston SJ, et al. Tumor necrosis factoralpha antagonists twenty years later: What do Cochrane reviews tell us? Inflamm Bowel Dis 2014;20:2132-41.
-
(2014)
Inflamm Bowel Dis
, vol.20
, pp. 2132-2141
-
-
Akobeng, A.A.1
Sandborn, W.J.2
Bickston, S.J.3
-
7
-
-
84866122837
-
Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry
-
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22.
-
(2012)
Am J Gastroenterol
, vol.107
, pp. 1409-1422
-
-
Lichtenstein, G.R.1
Feagan, B.G.2
Cohen, R.D.3
-
8
-
-
84925485488
-
Vedolizumab: A review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease
-
Garnock-Jones KP. Vedolizumab: A review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. BioDrugs 2015;29:57-67.
-
(2015)
BioDrugs
, vol.29
, pp. 57-67
-
-
Garnock-Jones, K.P.1
-
9
-
-
0030802049
-
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue
-
Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
-
(1997)
Am J Pathol
, vol.151
, pp. 97-110
-
-
Briskin, M.1
Winsor-Hines, D.2
Shyjan, A.3
-
10
-
-
84867576762
-
Exclusive antagonism of the a4ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
-
Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the a4ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012;18:2107-19.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 2107-2119
-
-
Fedyk, E.R.1
Wyant, T.2
Yang, L.L.3
-
11
-
-
70349086185
-
The binding specificity and selective antagonism of vedolizumab, an anti-a4ß7 integrin therapeutic antibody in development for inflammatory bowel diseases
-
Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-a4ß7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75.
-
(2009)
J Pharmacol Exp Ther
, vol.330
, pp. 864-875
-
-
Soler, D.1
Chapman, T.2
Yang, L.L.3
-
12
-
-
0029826678
-
Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin a4ß7
-
Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin a4ß7. Gastroenterology 1996;111:1373-80.
-
(1996)
Gastroenterology
, vol.111
, pp. 1373-1380
-
-
Hesterberg, P.E.1
Winsor-Hines, D.2
Briskin, M.J.3
-
13
-
-
84929773619
-
Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
-
Wyant T, Estevam J, Yang L, Rosario M. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 2016;90:168-76.
-
(2016)
Cytometry B Clin Cytom
, vol.90
, pp. 168-176
-
-
Wyant, T.1
Estevam, J.2
Yang, L.3
Rosario, M.4
-
14
-
-
84882769357
-
Vedolizumab as induction and maintenance therapy for ulcerative colitis
-
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
-
(2013)
N Engl J Med
, vol.369
, pp. 699-710
-
-
Feagan, B.G.1
Rutgeerts, P.2
Sands, B.E.3
-
15
-
-
0003871544
-
World Medical Association [WMA] Declaration of Helsinki -ethical principles for medical research involving human subjects
-
Accessed December 22
-
World Medical Association. World Medical Association [WMA] Declaration of Helsinki -ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ Accessed December 22, 2014.
-
(2014)
-
-
-
16
-
-
84884538154
-
Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease
-
Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1691-9.
-
(2013)
Inflamm Bowel Dis
, vol.19
, pp. 1691-1699
-
-
Parikh, A.1
Fox, I.2
Leach, T.3
-
17
-
-
84986574933
-
Risk assessment and minimization for progressive multifocal leukoencephalopathy (PML) (RAMP): A program to assess the potential early signs and symptoms of PML during clinical development of vedolizumab
-
Clifford D, McAuliffe M, Stephens K, et al. Risk assessment and minimization for progressive multifocal leukoencephalopathy (PML) (RAMP): A program to assess the potential early signs and symptoms of PML during clinical development of vedolizumab. Am J Gastroenterol 2013;108:S502.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. S502
-
-
Clifford, D.1
McAuliffe, M.2
Stephens, K.3
-
18
-
-
58149388237
-
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial
-
Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 3132-3141
-
-
Loftus, E.V.1
Feagan, B.G.2
Colombel, J.F.3
-
19
-
-
63849147312
-
Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease
-
Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment Pharmacol Ther 2009;29:1032-41.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 1032-1041
-
-
Coteur, G.1
Feagan, B.2
Keininger, D.L.3
Kosinski, M.4
-
20
-
-
84931563838
-
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
-
Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2015;42:188-202.
-
(2015)
Aliment Pharmacol Ther
, vol.42
, pp. 188-202
-
-
Rosario, M.1
Dirks, N.L.2
Gastonguay, M.R.3
-
21
-
-
85029021557
-
Corticosteroid dose reduction in ulcerative colitis patients treated with vedolizumab during the GEMINI 1 trial
-
Loftus EV, Siegel C, Panaccione R, et al. Corticosteroid dose reduction in ulcerative colitis patients treated with vedolizumab during the GEMINI 1 trial. Am J Gastroenterol 2015;110:S790.
-
(2015)
Am J Gastroenterol
, vol.110
, pp. S790
-
-
Loftus, E.V.1
Siegel, C.2
Panaccione, R.3
-
22
-
-
2442560536
-
The Inflammatory Bowel Disease Questionnaire: A review of its national validation studies
-
Pallis AG, Mouzas IA, Vlachonikolis IG. The Inflammatory Bowel Disease Questionnaire: A review of its national validation studies. Inflamm Bowel Dis 2004;10:261-9.
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 261-269
-
-
Pallis, A.G.1
Mouzas, I.A.2
Vlachonikolis, I.G.3
-
23
-
-
0036863322
-
Validation of the EuroQol questionnaire in patients with inflammatory bowel disease
-
Konig HH, Ulshofer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:1205-15.
-
(2002)
Eur J Gastroenterol Hepatol
, vol.14
, pp. 1205-1215
-
-
Konig, H.H.1
Ulshofer, A.2
Gregor, M.3
-
24
-
-
1942473594
-
A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis
-
McColl E, Han SW, Barton JR, Welfare MR. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004;13:805-11.
-
(2004)
Qual Life Res
, vol.13
, pp. 805-811
-
-
McColl, E.1
Han, S.W.2
Barton, J.R.3
Welfare, M.R.4
-
25
-
-
84886946831
-
Optimizing anti-TNF treatments in inflammatory bowel disease
-
Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014;13:24-30.
-
(2014)
Autoimmun Rev
, vol.13
, pp. 24-30
-
-
Ben-Horin, S.1
Kopylov, U.2
Chowers, Y.3
-
26
-
-
85029043209
-
-
Takeda. Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.
-
Takeda. Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2014.
-
(2014)
-
-
-
27
-
-
85028977058
-
Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease
-
Sands BE, Dubinsky M, Vermeire S, et al. Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2014;109:S478-S9.
-
(2014)
Am J Gastroenterol
, vol.109
, pp. S478-S479
-
-
Sands, B.E.1
Dubinsky, M.2
Vermeire, S.3
-
28
-
-
84866457923
-
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease
-
quiz e85-6
-
Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87; quiz e85-6.
-
(2012)
Clin Gastroenterol Hepatol
, vol.10
, pp. 1079-1087
-
-
Ordas, I.1
Feagan, B.G.2
Sandborn, W.J.3
-
29
-
-
79953788656
-
Assessing response and loss of response to biological therapies in IBD
-
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 685-698
-
-
Yanai, H.1
Hanauer, S.B.2
-
30
-
-
84960145681
-
The safety of vedolizumab for ulcerative colitis and Crohn's disease
-
Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016. doi: 10.1136/ gutjnl-2015-311079. [Epub ahead of print].
-
Gut
, vol.2016
-
-
Colombel, J.F.1
Sands, B.E.2
Rutgeerts, P.3
|